High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

AIMS: To retrospectively assess factors associated with John Cunningham virus (JCV) seroconversion in natalizumab-treated patients. BACKGROUND: Natalizumab is highly effective for the treatment of relapsing–remitting multiple sclerosis (RRMS), but its use is complicated by opportunistic JCV infectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Dwyer, Christopher M., Jokubaitis, Vilija G., Stankovich, Jim, Baker, Josephine, Haartsen, Jodi, Butzkueven, Helmut, Cartwright, Adriana, Shuey, Neil, Fragoso, Yara Dadalti, Rath, Louise, Skibina, Olga, Fryer, Kylie, Butler, Ernest, Coleman, Jennifer, MacIntrye, Jennifer, Macdonell, Richard, van der Walt, Anneke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053827/
https://www.ncbi.nlm.nih.gov/pubmed/33948117
http://dx.doi.org/10.1177/1756286421998915

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8053827/
https://www.ncbi.nlm.nih.gov/pubmed/33948117
http://dx.doi.org/10.1177/1756286421998915

Ejemplares similares